Better Buy: Biogen vs. Eli Lilly

Biogen (NASDAQ: BIIB) and Eli Lilly (NYSE: LLY) have a lot in common. Both companies are among the leaders in the biotech industry. Both have deep lineups and pipelines. And both are looking to dominate an area with a severe and growing need for new therapies: Alzheimer's disease (AD).

However, these two stocks have moved in very different directions over the past three years, with Eli Lilly delivering substantially better returns to its shareholders. Will that continue to be the case? Or will Biogen be the better performer from here on out?

Source Fool.com

Biogen Inc. Aktie

Heute erlebt Biogen Inc. einen merklichen Gewinn von 2,46 %.
Die Biogen Inc. Aktie ist im Trend: Deutlich mehr Buy- als Sell-Einschätzungen.
Das Kursziel von 287 € für Biogen Inc. bedeutet eine deutliche Steigerung von über 50% gegenüber dem aktuellen Kurs von 185.6 €.

Like: 0

BIIB

Teilen